NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $7.76 +0.11 (+1.44%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.60▼$7.8250-Day Range$7.60▼$10.7052-Week Range$7.52▼$13.09Volume742,479 shsAverage Volume1.03 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside325.3% Upside$33.00 Price TargetShort InterestBearish6.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.40Based on 5 Articles This WeekInsider TradingSelling Shares$43,800 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.26) to ($3.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector626th out of 910 stocksBiological Products, Except Diagnostic Industry101st out of 155 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.40% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 13.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 1.4 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search Interest6 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,800.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.26) to ($3.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesSeptember 5 at 3:16 PM | theglobeandmail.comGlobal Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 - The Globe and MailSeptember 5 at 10:14 AM | bizjournals.comKaliVir Immunotherapeutics appoints CFO as cancer treatment company prepares for clinical trialsSeptember 7, 2024 | WealthPress (Ad)This new buy indicator has the internet shook. In the last few weeks we’ve seen countless people talking about a totally new stock indicator called Platform X… It identifies the markets strongest stocks, then delivers customized buy signals for those stocks… Even as the market stalled out it nailed several calls including a 100%+ winner on Newmont mining… At first we thought this was some sort of hocus pocus indicator… But it turned out to be a very viable tool for trading today’s market action… Which is the reason for today's email…September 4 at 10:27 AM | tmcnet.comGlobal Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031August 30, 2024 | msn.comBioMarin slashes 124 more jobs in Bay Area as wave of biotech layoffs continuesAugust 29, 2024 | finance.yahoo.comGate Bioscience Appoints Industry Veteran Jeff Hatfield to Board of DirectorsAugust 27, 2024 | msn.comBay Area biotech firm lays off dozens more scientists just months after 436-worker cutAugust 26, 2024 | sg.finance.yahoo.comVIR Sep 2024 7.500 call (VIR240920C00007500)September 7, 2024 | WealthPress (Ad)This new buy indicator has the internet shook. In the last few weeks we’ve seen countless people talking about a totally new stock indicator called Platform X… It identifies the markets strongest stocks, then delivers customized buy signals for those stocks… Even as the market stalled out it nailed several calls including a 100%+ winner on Newmont mining… At first we thought this was some sort of hocus pocus indicator… But it turned out to be a very viable tool for trading today’s market action… Which is the reason for today's email…August 22, 2024 | finance.yahoo.comVir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 17, 2024 | finance.yahoo.comVIR Sep 2024 7.500 put (VIR240920P00007500)August 6, 2024 | msn.comSan Francisco biotech companies slash hundreds of jobs amid restructuring waveAugust 6, 2024 | 247wallst.comPrediction: This Pharma Stock Will Be the Best Performer the Rest of 2024August 5, 2024 | ca.finance.yahoo.comVIR Aug 2024 7.500 callAugust 4, 2024 | markets.businessinsider.comWeekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO BidAugust 3, 2024 | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | msn.comVir Biotechnology, San Francisco firm worth $1.3 billion, lays off 141 workersAugust 2, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Vir Biotechnology (VIR)See More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+325.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-612.40% Pretax Margin-624.10% Return on Equity-30.93% Return on Assets-26.01% Debt Debt-to-Equity RatioN/A Current Ratio12.51 Quick Ratio12.51 Sales & Book Value Annual Sales$57.65 million Price / Sales18.31 Cash FlowN/A Price / Cash FlowN/A Book Value$10.49 per share Price / Book0.74Miscellaneous Outstanding Shares136,059,000Free Float114,834,000Market Cap$1.06 billion OptionableOptionable Beta0.46 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Marianne De Backer M.B.A. (Age 55)M.Sc., Ph.D., CEO & Director Comp: $4.47MMr. Sung H. Lee (Age 54)Executive VP & CFO Comp: $968.45kDr. Ann M. Hanly Ph.D. (Age 54)Executive VP & Chief Technology Officer Comp: $896.07kDr. Jeff Calcagno M.D. (Age 63)Executive VP & Chief Business Officer Comp: $860.49kDr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorDr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEbluebird bioNASDAQ:BLUECRISPR TherapeuticsNASDAQ:CRSPADMA BiologicsNASDAQ:ADMAArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 14,900 shares on 8/19/2024Ownership: 0.013%Algert Global LLCBought 166,835 shares on 8/16/2024Ownership: 0.123%The Manufacturers Life Insurance Company Bought 3,605 shares on 8/15/2024Ownership: 0.036%Point72 Hong Kong LtdBought 12,598 shares on 8/15/2024Ownership: 0.014%AQR Capital Management LLCSold 11,022 shares on 8/15/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has decreased by 22.9% and is now trading at $7.76. View the best growth stocks for 2024 here. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings results on Thursday, August, 1st. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.13. The company's revenue was down 19.0% compared to the same quarter last year. What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's top institutional investors include Baillie Gifford & Co. (2.88%), Renaissance Technologies LLC (0.98%), Millennium Management LLC (0.92%) and Bank of New York Mellon Corp (0.60%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Phillip Pang, Howard Horn, Johanna Friedl-Naderer, Ann M Hanly, George A Scangos, Steven J Rice, Sung Lee, Saira Ramasastry, Charles Elliott Sigal, Janet Napolitano and Herbert Virgin. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
